Why Hims & Hers Stock Sank This Week

Hims & Hers reported record Q2 2025 revenue exceeding $500 million, marking 73% year-over-year growth and contributing to a 400% stock increase over five years. However, shares recently fell 17% due to a looming legal battle with Novo Nordisk. The telehealth platform is being sued for allegedly continuing to sell patented weight loss drugs after their supply shortage ended, a practice that constitutes a fast-growing part of its business. This significant legal exposure introduces substantial uncertainty regarding Hims & Hers' future revenue growth and profitability, prompting investor caution until the dispute is resolved.

Analysis

Hims & Hers Health (HIMS) is exhibiting a significant divergence between its fundamental growth and its legal risk profile. The company reported exceptional top-line performance in Q2 2025, with revenue surging 73% year-over-year to over $500 million, driven by a 30% increase in both total subscribers and spend per subscriber. This strong operational momentum has contributed to a 400% stock appreciation over the past five years. However, this growth narrative is now severely compromised by a lawsuit from Novo Nordisk. Hims & Hers is accused of illegally selling patented weight loss drugs, a practice described as a fast-growing segment of its business, after the official supply shortage concluded. The market has reacted negatively to this legal overhang, with the stock declining 17% in one week. The core issue for investors is that a key driver of recent growth is now a source of material legal and financial liability, creating substantial uncertainty around the sustainability of its future revenue and profitability.

Key Decisions for Investors

• Investors should recognize that the lawsuit from Novo Nordisk represents a material, unquantified risk that could significantly impair Hims & Hers' future revenue growth, as the contested weight loss drug sales are a key growth driver.
• Despite the strong 73% year-over-year revenue growth, the legal uncertainty makes the recent 17% stock drop a high-risk entry point, and it may be prudent to await clarity on the litigation's outcome before considering a position.
• Closely monitor all developments related to the patent infringement lawsuit, as any ruling or settlement will be a primary catalyst for the stock's direction, potentially overriding near-term financial results.